


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/743,818
		Filing Date	April 26, 2001
		First Named Inventor	Weiss et al
		Group Art Unit	1653 1656
		Examiner Name	H. SCHNIZER
Sheet 1 of 1	Attorney Docket Number	GHC11USA	

NONPATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
HS	DDY	IMAI ET AL, Expression of Membrane-Type 1 Matrix Metalloproteinase and Activation of Progelatinase A in Human Osteoarthritic Cartilage, American Journal of Pathology, Vol. 151, No. 1, (July 1997)	
HS	DDZ	D'ORTHO ET AL, Membrane-Type Matrix Metalloproteinases 1 and 2 Exhibit Broad-Spectrum Proteolytic Capacities Comparable to Many Matrix Metalloproteinases, Eur. J. Biochem. 250, pp. 751-757 (September 1997)	
HS	EEA	BINI ET AL, Degradation of Cross-Linked Fibrin by Matrix Metalloproteinase 3 (Stromelysin 1): Hydrolysis of the γ Gly 404-Ala 405 Peptide Bond, Biochemistry, Vol. 35, No. 40, pp. 13056-13063 (1996)	
HS	EEB	SHIPLEY ET AL, The Structural Basis for the Elastolytic Activity of the 92-kDa and 72-kDa Gelatinases, Vol. 271, No. 8, pp. 4335-4341, (February 1996)	
HS	EEC	MECHAM ET AL, Elastin Degradation by Matrix Metalloproteinases, Vol. 272, No. 29, pp. 18071-18076, (July 1997)	
HS	EED	CHANDLER ET AL, Macrophage Metalloelastase Degrades Matrix and Myelin Proteins and Processes a Tumour Necrosis Factor- α Fusion Protein, Biochemical and Biophysical Research Communications, 228, pp. 421-429 (1996)	
HS	EEE	XIA ET AL, Comparison of Cleavage Site Specificity of Gelatinases A and B Using Collagenous Peptides, Biochimica et Biophysica Acta 1293, pp. 259-266, (1996)	
HS	EEF	YOUNG ET AL, Characterization of Gelatinases Linked to Extracellular Matrix Invasion in Ovarian Adenocarcinoma: Purification of Matrix Metalloproteinase 2, Article No. 0195, Gynecologic Oncology, 62, 89-99, (1996)	
HS	EEH	BELLÓN ET AL, Study of Biochemical Substrate and Role of Metalloproteinases in Fascia Transversalis from Hernial Processes, European Journal of Clinical Investigation, Vol. 27(6), pp. 510-516, (June 1997)	

Examiner Signature		Date Considered	8-9-05
--------------------	---	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.